Osteoporosis
Teriparatide Injection
product description
Mechanism of Action:
Teriparatide works by activating the parathyroid hormone 1 receptor on osteoblasts, the cells responsible for bone formation. This activation leads to an increase in bone remodeling, with a net gain in bone mass. It uniquely promotes the growth of both trabecular and cortical bone, enhancing skeletal architecture and strength.
Indications and Usage:
Approved for the treatment of osteoporosis in postmenopausal women and men at high risk for fracture, Teriparatide is also indicated for individuals who have failed or are intolerant to other osteoporosis therapies. Additionally, it's used in patients with glucocorticoid-induced osteoporosis, enhancing bone mass in individuals undergoing long-term steroid treatment.
Administration and Dosage:
Teriparatide is administered via subcutaneous injection, typically at a dose of 20 micrograms once daily. The duration of treatment is generally limited to 24 months, based on the assessment of the benefits and potential risks.
Efficacy and Outcomes:
Studies demonstrate that Teriparatide significantly increases bone mineral density and reduces the incidence of vertebral and non-vertebral fractures among patients with osteoporosis. Its capacity to stimulate new bone formation sets it apart from other treatments that primarily reduce bone resorption.
Side Effects:
The most common side effects include nausea, leg cramps, and dizziness. Injection site reactions are also reported. A black box warning exists for potential osteosarcoma risk, based on animal studies, hence its restricted use to individuals for whom the potential benefits outweigh the risks.
Contraindications and Precautions:
Teriparatide is contraindicated in individuals with hypercalcemia, bone metastases, or a history of skeletal malignancies. Caution is advised in patients with severe renal impairment or those at increased risk for osteosarcoma.